SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending after confirming its pivotal REGAL trial has reached 78 of 80 required events, signaling that final clinical trial data is imminent. The community is actively debating the potential for a significant short squeeze due to high short interest and discussing the long-term potential of the GPS treatment platform for AML patients.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors digest news that CEO Jensen Huang is joining President Trump's delegation to China, sparking intense community debate over potential chip sales and export restrictions. The stock is seeing significant institutional support ahead of upcoming earnings, with traders closely monitoring the potential impact of high-level trade negotiations on future revenue growth.

WORK Medical Technology Group Ltd. engages in the development of health instruments. It manufactures and sells medical devices, including endotracheal tubes, laryngeal mask airways, heat and moisture exchanging filters, disposable breathing circuits, nebulizer kits, and yankauer suction sets. The company was founded on March 1, 2022 and is headquartered in Hangzhou, China.

Work Medical Technology Group Ltd - Ordinary Shares - Class A

Work Medical Technology Group Ltd

Work Medical Technology Group Ltd (WOK) is experiencing intense volatility and extreme upward price movement, driven by retail traders participating in a speculative 'China penny' momentum theme. The community remains deeply divided, with bulls targeting double-digit gains fueled by short squeezes and micro-float dynamics, while bears warn of a recurring 'retail robbery' cycle characterized by dilution, rapid share consolidation, and aggressive sell-offs.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is seeing intense retail activity as traders weigh a parabolic rally against fears of a potential 'blow-off top' in the semiconductor sector. Much of the community conversation is split between aggressive dip-buying and short-sellers betting on a technical mean reversion, with many investors actively debating the sustainability of the current AI-fueled demand cycle.

About Mistery On Cro $MERY was born with the idea of being a meme coin on Cronos chain during the exploding 2024 meme coin season. The founder is David Bui, a well-known and seasoned #crofam $CRO investor on Cryptocom products and a big -well respected- personality on X. David minted “Mistery On CRO” on Cronos blockchain with the purpose of making this chain much better, more popular and specially more fun, but aside from serving as a mere “meme”, $MERY has the ultimate goal of also being a utility token that the founder and the team behind will push to bring many benefits to loyal hodlers. Launched in 27/3/2024 at Sydney, Australia, local time 21h00, the 690,000 $CRO presale sold out within 2 hours. The founder burned the LP to a dead wallet and the contract ownership was renounced. $MERY during its first week of launch got instant traction from the OG #crofam community who jumped in and secured bags. We are now a thriving community that will help nurturing and growing the project by sharing with more and more Web3 users.

Mistery

Mistery ($MERY) is trending as a prominent meme coin on the Cronos chain, driven by its tight correlation with $CRO and community-led narratives surrounding its decentralized structure and secure liquidity. Investors are actively discussing the project's long-term potential, frequently highlighting significant holdings by the crypto.com/us exchange as a key indicator of its stability and growth prospects.

Wolfspeed, Inc. is an innovator of wide bandgap semiconductors, focused on silicon carbide and gallium nitride (GaN) materials and devices for power and radiofrequency (RF) applications. Its product families include silicon carbide and GaN materials, power devices and RF devices, and its products are targeted for various applications such as electric vehicles, fast charging, 5G, renewable energy and storage, and aerospace and defense. The company was founded by Calvin H. Carter Jr., John W. Palmour, F. Neal Hunter, Eric Hunter, and John Edmond in 1987 and is headquartered in Durham, NC.

Wolfspeed Inc - Ordinary Shares (New)

Wolfspeed Inc

Wolfspeed is experiencing significant volatility and aggressive short-term trading as investors debate its potential for a recovery or a secondary bankruptcy event following recent restructuring. The community is sharply divided, with bulls pointing to the company's silicon carbide technology and strategic positioning in AI data centers, while bears emphasize the ongoing lack of profitability and the history of shareholder dilution.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology remains the center of intense market attention as traders aggressively buy the dip, fueled by the conviction that surging AI-driven memory demand and potential supply constraints from a Samsung labor strike will drive long-term upside. The community is actively debating the sustainability of this rally, with bulls citing a low forward price-to-earnings ratio and institutional accumulation while bears warn of technical overextension and potential cyclical risks.

Roundhill ETF Trust - Roundhill Memory ETF

The Roundhill Memory ETF (DRAM) is surging as investors aggressively capitalize on a multi-year memory chip shortage driven by surging demand for AI infrastructure and HBM. The community remains overwhelmingly bullish, dismissing recent volatility as a buying opportunity while highlighting record-breaking asset inflows and the critical role of the fund's major holdings in the AI supply chain.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors anticipate upcoming earnings, with community sentiment divided between excitement over the company's full-stack infrastructure expansion and concerns regarding potential market volatility. While some focus on long-term value and recent infrastructure milestones, others are actively debating the stock's valuation, insider activity, and its correlation with other data center peers ahead of the print.

Enhanced Group, Inc. is an elite sports competition and performance products company committed to providing athletes and consumers with products that support health, performance, and recovery. The company offers a portfolio of products and experiences that combine athletic competition, scientific innovation, and consumer engagement. The company is headquartered in New York, NY.

Enhanced Group Inc. - Ordinary Shares - Class A

Enhanced Group Inc

Enhanced Group Inc is gaining significant traction following its recent NYSE listing as investors and followers track the countdown to its inaugural athletic event in Las Vegas. Community sentiment is largely focused on the company's strategic partnership to broadcast the event via a major streaming platform, viewing the games as a high-profile marketing catalyst to drive user acquisition for their telehealth and performance-science business.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cronos Group (CRON) Q1 Earnings Meet Estimates

Cronos (CRON) delivered earnings and revenue surprises of 0.00% and +6.94%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +23.94% and +7.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 Earnings Expected to Decline

ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ARS Pharmaceuticals (SPRY) Projected to Post Quarterly Earnings on Wednesday

ARS Pharmaceuticals (NASDAQ:SPRY) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at...

Q1 Earnings Forecast for SPRY Issued By Northland Securities

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Analysts at Northland Securities issued their Q1 2026 EPS estimates for ARS Pharmaceuticals in a research note issued to investors on Thursday...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of "Hold" by Analysts

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have earned a consensus recommendation of "Hold" from the five analysts that are presently covering the stock, Marketbeat Ratings...

ARS Pharmaceuticals (NASDAQ:SPRY) Coverage Initiated by Analysts at Northland Securities

Northland Securities initiated coverage on shares of ARS Pharmaceuticals in a report on Thursday. They issued an "outperform" rating and a $25.00 price target on the stock...

Aberdeen Group plc Purchases 459,027 Shares of ARS Pharmaceuticals, Inc. $SPRY

Aberdeen Group plc raised its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 14.8% during the fourth quarter, according to its most recent disclosure with the Securities and...

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 8% - Should You Buy?

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 8% - Should You Buy...

ARS Pharmaceuticals (NASDAQ:SPRY)  Shares Down 5.7%   - Time to Sell?

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.7% - Here's What Happened...

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

Current Price	$8.63
Prev Close	$8.60
Open	$8.64
Dividend Yield	0.00%
50-Day Moving Average	$8.37
Beta	1.25
Avg. Volume	1.53M
PE Ratio	-4.97

52-Week High	$18.90
52-Week Low	$6.66
Market Capitalization	$853.96M
EPS (Annual)	-$1.74
Price to Book	7.50
Revenue Per Employee	$517,042.95

SPRY
ARS Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SPRY News

SPRYARS Pharmaceuticals Inc